Ani Pharmaceuticals (ANIP) Capital Expenditures (2010 - 2026)
Ani Pharmaceuticals (ANIP) posted Capital Expenditures of $6.1 million for Q1 2026, up 152.63% sequentially from -$11.5 million in Q4 2025, and up 494.32% YoY from $1.0 million in Q1 2025.
Ani Pharmaceuticals (ANIP) Capital Expenditures (2010 - 2026) Analysis & Trends
Ani Pharmaceuticals has reported Capital Expenditures for 17 years, with the latest figure at $6.1 million in Q1 2026.
- Quarterly Capital Expenditures rose 494.32% year-over-year to $6.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.1 million (up 1754.71% YoY) and the FY2025 annual result came in at $1.0 million, up 98.49% from the prior year.
- Capital Expenditures advanced to $6.1 million in Q1 2026 per ANIP's latest filing, from -$11.5 million in the prior quarter.
- Over five years, Capital Expenditures peaked at $12.2 million in Q3 2024 and troughed at -$13.3 million in Q4 2024.
- A 5-year average of $496058.8 and a median of $526000.0 in 2022 frame the typical range for Capital Expenditures.
- The sharpest annual moves came in 2024 and 2025: Capital Expenditures tumbled 16535.8% in 2024, then jumped 1280.3% in 2025.
- Over 5 years, Capital Expenditures stood at $248000.0 in 2022, then tumbled by 67.34% to $81000.0 in 2023, then sank by 16535.8% to -$13.3 million in 2024, then climbed by 13.31% to -$11.5 million in 2025, then jumped by 152.63% to $6.1 million in 2026.
- According to Business Quant data, Capital Expenditures over the past three periods registered $6.1 million, -$11.5 million, and $6.1 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.07 Bn | 43.10 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.41 Bn | 39.75 Bn | 2.15 Bn | 104.00 Mn |
| 3 | Zoetis | 31.83 Bn | 30.15 Bn | 1.05 Bn | 117.00 Mn |
| 4 | Takeda Pharmaceutical | 28.77 Bn | 22.97 Bn | 5.10 Bn | -337.60 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | 108.00 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 52.80 Mn |
| 7 | Neurocrine Biosciences | 15.65 Bn | 15.26 Bn | 935.80 Mn | 7.80 Mn |
| 8 | Elanco Animal Health | 11.93 Bn | 11.40 Bn | 798.00 Mn | 33.00 Mn |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 10.00 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.63 Bn | 1.27 Bn | 165.89 Mn | 3.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.05 Mn |
| Jun 30, 2026 | 3.05 Mn |
| Mar 31, 2026 | 6.07 Mn |
| Mar 31, 2026 | 6.07 Mn |
| Dec 31, 2025 | -11.54 Mn |
| Dec 31, 2025 | -11.54 Mn |
| Sep 30, 2025 | 6.10 Mn |
| Sep 30, 2025 | 6.10 Mn |
| Jun 30, 2025 | 5.47 Mn |
| Jun 30, 2025 | 5.47 Mn |
| Mar 31, 2025 | 1.02 Mn |
| Mar 31, 2025 | 1.02 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Dec 31, 2024 | -13.31 Mn |
| Sep 30, 2024 | 12.22 Mn |
| Sep 30, 2024 | 12.22 Mn |
| Jun 30, 2024 | 396,000.00 |
| Jun 30, 2024 | 396,000.00 |
| Mar 31, 2024 | 1.22 Mn |
| Mar 31, 2024 | 1.22 Mn |